Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sunshine Biopharma Inc. - Common stock (NQ:SBFM)

1.510 -0.040 (-2.57%)
Streaming Delayed Price Updated: 1:57 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sunshine Biopharma Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Sunshine Biopharma Stock Soars After Launch Of First Biosimilar In $10B Canadian Market: Retail Bulls Charge In
The company launched Niopeg, a biosimilar to Neulasta, designed to reduce the risk of infection in chemotherapy patients. 
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market
Via ACCESS Newswire
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’
CEO Steve Slilaty stated that the company is aiming to strengthen its presence in Canada’s generic drugs market, valued at $9.4 billion. 
Via Stocktwits
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market
Via ACCESS Newswire
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year
Via ACCESS Newswire
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market
Via ACCESS Newswire
Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug
Its subsidiary launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market. 
Via Stocktwits
The market is filled with gapping stocks in Monday's session.
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
What's going on in today's pre-market session
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
Via ACCESS Newswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Secures $2.46M in Registered Direct
Via Investor Brand Network
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
Via ACCESS Newswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug
Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 million. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer
Via ACCESS Newswire
US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia
U.S. stock futures slipped on Wednesday after a mixed session on Tuesday. Futures of major benchmark indices were lower in premarket trading. 
Via Benzinga
Why Sportsman's Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
Via ACCESS Newswire
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
Via ACCESS Newswire
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
Via ACCESS Newswire
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
Via ACCESS Newswire
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
Via ACCESSWIRE
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
Via ACCESSWIRE
Sunshine Biopharma Launches a New Generic Prescription Drug
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.